Analysts Set Expectations for Edesa Biotech Q2 Earnings

Edesa Biotech, Inc. (NASDAQ:EDSA) – HC Wainwright issued their Q2 2025 earnings per share estimates for shares of Edesa Biotech in a research note issued to investors on Thursday, March 13th. HC Wainwright analyst V. Bernardino expects that the company will post earnings of ($0.42) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $21.00 price objective on the stock. The consensus estimate for Edesa Biotech’s current full-year earnings is ($1.75) per share. HC Wainwright also issued estimates for Edesa Biotech’s Q3 2025 earnings at ($0.36) EPS, Q4 2025 earnings at ($0.41) EPS and FY2025 earnings at ($1.63) EPS.

Edesa Biotech (NASDAQ:EDSA) last posted its earnings results on Friday, February 14th. The company reported ($0.48) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.17). During the same period last year, the business earned ($0.54) earnings per share.

Edesa Biotech Trading Down 2.5 %

EDSA stock opened at $2.38 on Monday. The firm has a market capitalization of $16.64 million, a PE ratio of -1.27 and a beta of 0.77. Edesa Biotech has a 1-year low of $1.55 and a 1-year high of $5.59. The business’s 50 day simple moving average is $2.11 and its 200 day simple moving average is $2.74.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Edesa Biotech stock. Two Sigma Securities LLC acquired a new stake in Edesa Biotech, Inc. (NASDAQ:EDSA) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 15,313 shares of the company’s stock, valued at approximately $26,000. Two Sigma Securities LLC owned approximately 0.44% of Edesa Biotech at the end of the most recent reporting period. 5.50% of the stock is currently owned by institutional investors and hedge funds.

About Edesa Biotech

Edesa Biotech, Inc, a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis.